Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01215344
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Tennessee Cancer Institute, Boston Baskin Cancer Group, Memphis, Tennessee, United States
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Conditions
- Interventions
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Paul Richardson, MD
- Target Recruit Count
- 729
- Registration Number
- NCT01208662
- Locations
- 🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT01207921
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 127
- Registration Number
- NCT01208051
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01200004
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 111
- Registration Number
- NCT01197560
- Locations
- 🇺🇸
Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Australia
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 4
- Registration Number
- NCT01198054
- Locations
- 🇪🇸
Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸Hospital Clínico San Carlos de Madrid, Madrid, Spain
🇪🇸Hospital Ramón y Cajal. Madrid, Madrid, Spain
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
- Conditions
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT01194791
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Lozano Blesa, Zaragoza, Spain
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 180
- Registration Number
- NCT01183663
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT01180569
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.